What is pulmozyme primarily used for?

Pulmozyme, or dornase alfa, is primarily used for its ability to thin secretions in patients with cystic fibrosis (CF). This medication works by cleaving DNA in the thick mucus produced in the lungs of CF patients, thereby reducing mucus viscosity and aiding in the clearance of secretions. By breaking down the DNA that accumulates in the mucus due to the infection and inflammation commonly found in cystic fibrosis, Pulmozyme makes the mucus less sticky, facilitating easier expectoration and improving lung function.

The other options do not accurately reflect the primary use of Pulmozyme. While treatments for hypertension might utilize other specific medications, Pulmozyme is not indicated for this purpose. Increasing lung capacity typically involves different interventions or medications that help with airway dilation or lung expansion rather than mucus management. Finally, while asthma patients may experience mucus production, Pulmozyme is not primarily used to treat asthma; instead, asthma management focuses on bronchodilators and anti-inflammatory medications. Thus, the correct application of Pulmozyme is specifically within the context of treating cystic fibrosis-related mucus issues.